| 000 | 01011 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250518094108.0 | ||
| 264 | 0 | _c20201126 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1873-2763 | ||
| 024 | 7 |
_a10.1016/j.bone.2020.115271 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLv, Fang | |
| 245 | 0 | 0 |
_aResponse to "Denosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis". _h[electronic resource] |
| 260 |
_bBone _c05 2020 |
||
| 300 |
_a115271 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xepidemiology |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOsteoporosis _xdrug therapy |
| 700 | 1 | _aCai, Xiaoling | |
| 700 | 1 | _aJi, Linong | |
| 773 | 0 |
_tBone _gvol. 134 _gp. 115271 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bone.2020.115271 _zAvailable from publisher's website |
| 999 |
_c30816527 _d30816527 |
||